Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers

Cheng Chieh Yang; Adam Labaff; Yongkun Wei; Lei Nie; Weiya Xia; Longfei Huo; Hirohito Yamaguchi; Yi Hsin Hsu; Jennifer L. Hsu; Dongping Liu; Jingyu Lang; Yi Du; Huang Chun Lien; Long Yuan Li; Rong Deng; Li Chuan Chan; Jun Yao; Celina G. Kleer; Gabriel N. Hortobagyi; Mien Chie Hung

Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers

Cheng Chieh Yang, Adam Labaff, Yongkun Wei, Lei Nie, Weiya Xia, Longfei Huo, Hirohito Yamaguchi, Yi Hsin Hsu, Jennifer L. Hsu, Dongping Liu, Jingyu Lang, Yi Du, Huang Chun Lien, Long Yuan Li, Rong Deng, Li Chuan Chan, Jun Yao, Celina G. Kleer, Gabriel N. Hortobagyi, Mien Chie Hung

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

Triple-negative breast cancer (TNBC), which is closely related to basal-like breast cancer, is a highly aggressive subtype of breast cancer that initially responds to chemotherapy but eventually develops resistance. This presents a major clinical challenge as there are currently no effective targeted therapies available due to its lack of HER2 and estrogen receptor expression. Here, we show that cyclin E and the enhancer of zeste 2 (EZH2) are closely co-expressed in TNBC patients, and cyclin E/CDK2 phosphorylates EZH2 at T416 (pT416-EZH2) in vivo. Phosphorylation of EZH2 at T416 enhances the ability of EZH2 to promote TNBC cell migration/invasion, tumorsphere formation, and in vivo tumor growth. In addition, high pT416-EZH2 correlates with poorer survival in TNBC patients. These findings suggest that pT416 has the potential to serve as a therapeutic biomarker for the aggressive forms of breast cancer and provide a rationale for the use of CDK2 inhibitors to treat TNBC.

Original language	English (US)
Pages (from-to)	1009-1020
Number of pages	12
Journal	American Journal of Translational Research
Volume	7
Issue number	6
State	Published - Feb 25 2015

Keywords

CDK2
EZH2
Phosphorylation

ASJC Scopus subject areas

Molecular Medicine
Clinical Biochemistry
Cancer Research

Cite this

Yang, C. C., Labaff, A., Wei, Y., Nie, L., Xia, W., Huo, L., Yamaguchi, H., Hsu, Y. H., Hsu, J. L., Liu, D., Lang, J., Du, Y., Lien, H. C., Li, L. Y., Deng, R., Chan, L. C., Yao, J., Kleer, C. G., Hortobagyi, G. N., & Hung, M. C. (2015). Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers. American Journal of Translational Research, 7(6), 1009-1020.

Yang, CC, Labaff, A, Wei, Y , Nie, L, Xia, W, Huo, L, Yamaguchi, H, Hsu, YH, Hsu, JL, Liu, D, Lang, J, Du, Y, Lien, HC, Li, LY, Deng, R, Chan, LC, Yao, J, Kleer, CG, Hortobagyi, GN & Hung, MC 2015, 'Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers', American Journal of Translational Research, vol. 7, no. 6, pp. 1009-1020.

@article{fdd24b304c9140fdbd285529895434dd,

title = "Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers",

abstract = "Triple-negative breast cancer (TNBC), which is closely related to basal-like breast cancer, is a highly aggressive subtype of breast cancer that initially responds to chemotherapy but eventually develops resistance. This presents a major clinical challenge as there are currently no effective targeted therapies available due to its lack of HER2 and estrogen receptor expression. Here, we show that cyclin E and the enhancer of zeste 2 (EZH2) are closely co-expressed in TNBC patients, and cyclin E/CDK2 phosphorylates EZH2 at T416 (pT416-EZH2) in vivo. Phosphorylation of EZH2 at T416 enhances the ability of EZH2 to promote TNBC cell migration/invasion, tumorsphere formation, and in vivo tumor growth. In addition, high pT416-EZH2 correlates with poorer survival in TNBC patients. These findings suggest that pT416 has the potential to serve as a therapeutic biomarker for the aggressive forms of breast cancer and provide a rationale for the use of CDK2 inhibitors to treat TNBC.",

keywords = "CDK2, EZH2, Phosphorylation",

author = "Yang, {Cheng Chieh} and Adam Labaff and Yongkun Wei and Lei Nie and Weiya Xia and Longfei Huo and Hirohito Yamaguchi and Hsu, {Yi Hsin} and Hsu, {Jennifer L.} and Dongping Liu and Jingyu Lang and Yi Du and Lien, {Huang Chun} and Li, {Long Yuan} and Rong Deng and Chan, {Li Chuan} and Jun Yao and Kleer, {Celina G.} and Hortobagyi, {Gabriel N.} and Hung, {Mien Chie}",

year = "2015",

month = feb,

day = "25",

language = "English (US)",

volume = "7",

pages = "1009--1020",

journal = "American Journal of Translational Research",

issn = "1943-8141",

publisher = "e-Century Publishing Corporation",

number = "6",

}

TY - JOUR

T1 - Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers

AU - Yang, Cheng Chieh

AU - Labaff, Adam

AU - Wei, Yongkun

AU - Nie, Lei

AU - Xia, Weiya

AU - Huo, Longfei

AU - Yamaguchi, Hirohito

AU - Hsu, Yi Hsin

AU - Hsu, Jennifer L.

AU - Liu, Dongping

AU - Lang, Jingyu

AU - Du, Yi

AU - Lien, Huang Chun

AU - Li, Long Yuan

AU - Deng, Rong

AU - Chan, Li Chuan

AU - Yao, Jun

AU - Kleer, Celina G.

AU - Hortobagyi, Gabriel N.

AU - Hung, Mien Chie

PY - 2015/2/25

Y1 - 2015/2/25

N2 - Triple-negative breast cancer (TNBC), which is closely related to basal-like breast cancer, is a highly aggressive subtype of breast cancer that initially responds to chemotherapy but eventually develops resistance. This presents a major clinical challenge as there are currently no effective targeted therapies available due to its lack of HER2 and estrogen receptor expression. Here, we show that cyclin E and the enhancer of zeste 2 (EZH2) are closely co-expressed in TNBC patients, and cyclin E/CDK2 phosphorylates EZH2 at T416 (pT416-EZH2) in vivo. Phosphorylation of EZH2 at T416 enhances the ability of EZH2 to promote TNBC cell migration/invasion, tumorsphere formation, and in vivo tumor growth. In addition, high pT416-EZH2 correlates with poorer survival in TNBC patients. These findings suggest that pT416 has the potential to serve as a therapeutic biomarker for the aggressive forms of breast cancer and provide a rationale for the use of CDK2 inhibitors to treat TNBC.

AB - Triple-negative breast cancer (TNBC), which is closely related to basal-like breast cancer, is a highly aggressive subtype of breast cancer that initially responds to chemotherapy but eventually develops resistance. This presents a major clinical challenge as there are currently no effective targeted therapies available due to its lack of HER2 and estrogen receptor expression. Here, we show that cyclin E and the enhancer of zeste 2 (EZH2) are closely co-expressed in TNBC patients, and cyclin E/CDK2 phosphorylates EZH2 at T416 (pT416-EZH2) in vivo. Phosphorylation of EZH2 at T416 enhances the ability of EZH2 to promote TNBC cell migration/invasion, tumorsphere formation, and in vivo tumor growth. In addition, high pT416-EZH2 correlates with poorer survival in TNBC patients. These findings suggest that pT416 has the potential to serve as a therapeutic biomarker for the aggressive forms of breast cancer and provide a rationale for the use of CDK2 inhibitors to treat TNBC.

KW - CDK2

KW - EZH2

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=84939503541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939503541&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84939503541

SN - 1943-8141

VL - 7

SP - 1009

EP - 1020

JO - American Journal of Translational Research

JF - American Journal of Translational Research

IS - 6

ER -

Phosphorylation of ezh2 at t416 by cdk2 contributes to the malignancy of triple negative breast cancers

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this